Thrombolytic therapy for massive pulmonary embolism in a patient with a known intracranial tumor

Journal of Intensive Care Medicine

Volumn 21, Issue 4, 2006, Pages 240-245

  Han, Steve ^a   Chaya, Craig ^a   Soo Hoo, Guy W ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Alteplase; Glioblastoma multiforme; Intracranial tumor; Pulmonary embolism; Thrombolysis

Indexed keywords

ALTEPLASE; HEPARIN; WARFARIN;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; BRAIN HEMORRHAGE; CASE REPORT; FIBRINOLYTIC THERAPY; GASTROINTESTINAL HEMORRHAGE; GLIOBLASTOMA; HEMODYNAMICS; HUMAN; INCIDENCE; INTRACRANIAL TUMOR; LUNG BLOOD VESSEL; LUNG EDEMA; LUNG SCINTISCANNING; LUNG VENTILATION PERFUSION RATIO; MALE; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MORTALITY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM; TRANSTHORACIC ECHOCARDIOGRAPHY;

AGED; BRAIN NEOPLASMS; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; GLIOBLASTOMA; HEPARIN; HUMANS; MALE; PULMONARY EMBOLISM; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33745749465     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066606287047     Document Type: Article

References (41)

1. Wood KE. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest. 2002;121:877-905.
2. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;353: 1386-1389.
3. Kasper W, Konstantinides S, Geibel A, et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol. 1997;30:1165-1171.
4. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax. 2003;58:470-483.
5. Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):401S-442S.
6. Indications for fibrinolytic therapy in suspected acute myocarclial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet. 1994;343:311-322.
7. Sharma GV, Cella G, Parisi AF, et al. Thrombolytic therapy. N Engl J Med. 1982;306:1268-1276.
8. Goldhaber SZ, Kessler CM, Heit J, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet. 1988;2:293-298.
9. Abu-Laban RB, Christenson JM, Innes GD, et al. Tissue plasminogen activator in cardiac arrest with pulseless electrical activity. N Engl J Med. 2002;346:1522-1528.
10. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
11. Higashida RT, Furlan AJ, Roberts H, et al. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke. 2003;34:e109-e137.
12. Ottesen MM, Kober L, Jorgensen S, et al. Consequences of overutilization and underutilization of thrombolytic therapy in clinical practice. TRACE Study Group. TRAndolapril Cardiac Evaluation. J Am Coll Cardiol. 2001;37:1581-1587.
13. Bottiger BW, Padosch SA. Thrombolysis using recombinant tissue-type plasminogen activator during cardiopulmonary resuscitation in patients with out-of-hospital cardiac arrest. Resuscitation. 2002;52:308-309.
14. Cairns JA, Kennedy JW, Fuster V. Coronary thrombolysis. Chest. 1998;114(5 suppl):634S-657S.
15. Menon V, Harrington RA, Hochman JS, et al. Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):549S-575S.
16. Jaffe R, Reichman JM, Weiss AT, et al. Thrombolysis in the presence of an intracranial meningioma. Chest. 1997;111:258.
17. Sakai K, Ochiai H, Katayama N, et al. Catheter interventional therapy in an elderly patient with deep vein thrombosis and a brain tumor. Jpn Heart J. 2004;45:709-713.
18. Rubinshtein R, Jaffe R, Flugelman MY, et al. Thrombolysis in patients with a brain tumour. Heart. 2004;90:1476.
19. Kanter DS, Mikkola KM, Patel SR, et al. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest. 1997;111:1241-1245.
20. Kondziolka D, Bernstein M, Resch L, et al. Significance of hemorrhage into brain tumors: clinicopathological study. J Neurosurg. 1987;67:852-857.
21. Licata B, Turazzi S. Bleeding cerebral neoplasms with symptomatic hematoma. J Neurosurg Sci. 2003;47:201-210.
22. Bitoh S, Hasegawa H, Ohtsuki H, et al. Cerebral neoplasms initially presenting with massive intracerebral hemorrhage. Surg Neurol. 1984;22:57-62.
23. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet. 1994;343:311-322.
24. Gebel JM, Sila CA, Sloan MA, et al. Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Stroke. 1998;29: 563-569.
25. Arcasoy SM, Kreit JW. Thrombolytic therapy of pulmonary embolism: a comprehensive review of current evidence. Chest. 1999;115:1695-1707.
26. Simoons ML, Maggioni AP, Knatterud G, et al. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet. 1993;342:1523-1528.
27. Kurkciyan I, Meron G, Sterz F, et al. Pulmonary embolism as a cause of cardiac arrest: presentation and outcome. Arch Intern Med. 2000;160:1529-1535.
28. Bottiger BW, Bode C, Kern S, et al. Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopulmonary resuscitation: a prospective clinical trial. Lancet. 2001;357:1583-1585.
29. Lederer W, Lichtenberger C, Pechlaner C, et al. Recombinant tissue plasminogen activator during cardiopulmonary resuscitation in 108 patients with out-of-hospital cardiac arrest. Resuscitation. 2001;50:71-76.
30. Bailen MR, Cuadra JA, Aguayo DH. Thrombolysis during cardiopulmonary resuscitation in fulminant pulmonary embolism: a review. Crit Care Med. 2001;29:2211-2219.
31. Bottiger BW, Padosch SA, Wenzel V. Tissue plasminogen activator in cardiac arrest with pulseless electrical activity. N Engl J Med. 2002;347:1281-1282.
32. Janata K, Holzer M, Kurkciyan I, et al. Major bleeding complications in cardiopulmonary resuscitation: the place of thrombolytic therapy in cardiac arrest due to massive pulmonary embolism. Resuscitation. 2003;57:49-55.
33. Krivec B, Voga G, Zuran I, et al. Diagnosis and treatment of shock due to massive pulmonary embolism: approach with transesophageal echocardiography and intrapulmonary thrombolysis. Chest. 1997;112:1310-1316.
34. Kurkciyan I, Meron G, Sterz F, et al. Pulmonary embolism as a cause of cardiac arrest: presentation and outcome. Arch Intern Med. 2000;160:1529-1535.
35. Rose PS, Punjabi NM, Pearse DB. Treatment of right heart thromboemboli. Chest. 2002;121:806-814.
36. Tarry WC, Makhoul RG, Tisnado J, et al. Catheter-directed thrombolysis following vena cava filtration for severe deep venous thrombosis. Ann Vasc Surg. 1994;8:583-590.
37. Olin JW, Young JR, Graor RA, et al. Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors. Anticoagulants or inferior vena cava filter? Arch Intern Med. 1987;147:2177-2179.
38. Choucair AK, Silver P, Levin VA. Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism. J Neurosurg. 1987;66:357-358.
39. Levin JM, Schiff D, Loeffler JS, et al. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology. 1993;43:1111-1114.
40. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348:1425-1434.
41. Annegers JF, Schoenberg BS, Okazaki H, et al. Epidemiologic study of primary intracranial neoplasms. Arch Neurol. 1981; 38:217-219.